Tickers

1. Composite Trajectory Verdict

For a low-margin, working-capital-intensive distributor, all three statements carry weight but cash generation and balance-sheet liquidity are especially critical given the reliance on a revolving credit facility to fund inventory and receivables.

Composite Trajectory: Mixed

The annual income statement shows deterioration (net income -13.4%, operating income -9.7% year-over-year), while the most recent quarter shows net income growth (+24.8%) despite operating income decline. Cash generation deteriorated sharply: annual operating cash flow swung to -$1.7M from +$26.8M, and nine-month operating cash flow fell 54% to $7.3M. The balance sheet is mixed: equity rose 13% and working capital expanded 37%, but revolver borrowings increased 33% to $74M with availability falling to $46M, and inventory grew 23% to $126.6M.

2. Red Flags

• Annual operating cash flow turned negative -$1.7M vs +$26.8M prior year, driven by a $23.8M inventory build and $17.5M receivables increase (10-K FY2026, Consolidated Statements of Cash Flows).
• GAAP net income fell 13.4% to $13.1M despite 8% revenue growth, primarily due to a $7.8M vendor receivable write-off and 22% operating expense growth (10-K FY2026, Consolidated Statements of Operations).
• Q3 gross margin compressed 80 bps to 12.8% from 13.6% despite 21% revenue growth (10-Q Q3 FY2026, MD&A Results of Operations).
• Revolving credit facility balance increased 33% to $74M at June 30, 2026 from $57M, while availability declined to $46M from $54M (10-K FY2026, Liquidity and Capital Resources).
• Warrant liability grew to $2.075M at March 31, 2026 from $646K at June 30, 2025, with non-cash fair value changes creating earnings volatility (10-Q Q3 FY2026, Note 22).
• Customer concentration increased: Customer #1 represented 22.5% of Q3 revenue vs 14.8% prior year (10-Q Q3 FY2026, Note 2 Concentration of Credit Risk).
• Contingent consideration liability of $5.5M recorded for Endstate acquisition (10-Q Q3 FY2026, Note 23).

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Mixed

Annual FY2026 net revenue rose 8% to $1.149B from $1.063B, and gross margin expanded 80 bps to 13.3% (10-K FY2026, Consolidated Statements of Operations). However, operating income declined 9.7% to $27.2M from $30.1M and net income fell 13.4% to $13.1M from $15.1M, reflecting a $7.8M vendor transaction loss and 22% higher total operating expenses (10-K FY2026, MD&A). In the most recent quarter (Q3 FY2026), net revenue grew 21% to $258.2M but gross margin compressed 80 bps to 12.8%, operating income dipped 6% to $3.3M, while net income rose 25% to $2.3M aided by lower interest expense and a warrant gain (10-Q Q3 FY2026, Consolidated Statements of Operations). Nine-month results show strong improvement with net income up 78% to $16.6M, but the implied Q4 loss (~$3.5M) pulls the full year into negative territory.

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Deteriorating

Annual operating cash flow swung to -$1.7M from +$26.8M, a $28.5M deterioration, as working capital absorbed cash: inventory increased $23.8M (vs $4.7M prior year) and trade receivables rose $17.5M (vs $6.1M), partially offset by a $15.7M payables increase (10-K FY2026, Consolidated Statements of Cash Flows). Nine-month operating cash flow fell 54% to $7.3M from $16.1M, with inventory using $23.8M (vs $5.0M source prior year) and payables providing only $3.2M (vs $6.4M) (10-Q Q3 FY2026, Consolidated Statements of Cash Flows). Investing outflows moderated to -$2.0M from -$8.1M annually and -$2.1M from -$7.6M nine-month, reflecting lower acquisition spending. Financing flipped to +$3.3M annually from -$18.6M, driven by net revolver borrowings of $17M to fund working capital.

5. Balance Sheet Assessment

Balance Sheet Trajectory: Mixed

Total assets grew 10% to $397.6M at June 30, 2026 from $361.2M, with equity rising 13% to $116.6M and working capital expanding 37% to $62.4M (10-K FY2026, Consolidated Balance Sheets). However, the revolver balance increased 33% to $74M, reducing availability to $46M from $54M. Inventory rose 23% to $126.6M and accounts receivable 17% to $111.0M, while accounts payable grew only 10% to $171.0M. At March 31, 2026, inventory stood at $126.7M (up 23% from June 30, 2025), revolver at $64.3M (up 16%), and equity at $120.0M (up 16%) (10-Q Q3 FY2026, Consolidated Balance Sheets). Warrant liability increased to $2.1M from $0.6M, and a $5.5M contingent consideration liability was added for the Endstate acquisition.

6. Data Gaps

• Standalone Q4 FY2026 (April–June 2026) income statement and cash flow statement to explain the full-year vs nine-month divergence.
• Quarterly (three-month) cash flow statements for Q3, Q2, and Q1 FY2026 (only nine-month YTD provided in 10-Qs).
• Detailed breakdown of the $10.2M SG&A increase in FY2026 (public company costs, strategic initiatives, payroll).
• Full-year FY2025 quarterly trends (only Q3 FY2025 10-Q provided; Q1/Q2 FY2025 10-Qs not included).
• Reconciliation of the implied Q4 operating loss and its drivers (vendor loss timing, seasonality, etc.).